REAL

Transfer of complex regional pain syndrome to mice via human autoantibodies is mediated by interleukin-1-induced mechanisms

Helyes, Zsuzsanna and Tékus, Valéria and Szentes, Nikolett and Pohóczky, Krisztina and Botz, Bálint and Kemény, Ágnes and Környei, Zsuzsanna and Tóth, Krisztina and Lénárt, Nikolett and Ábrahám, Hajnalka and Dénes, Ádám (2019) Transfer of complex regional pain syndrome to mice via human autoantibodies is mediated by interleukin-1-induced mechanisms. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 116 (26). pp. 13067-13076. ISSN 0027-8424

[img] Text
Helyes_PNAS_2019.pdf
Restricted to Registered users only

Download (1MB) | Request a copy

Abstract

Neuroimmune interactions may contribute to severe pain and regional inflammatory and autonomic signs in complex regional pain syndrome (CRPS), a posttraumatic pain disorder. Here, we investigated peripheral and central immune mechanisms in a translational passive transfer trauma mouse model of CRPS. Small plantar skin-muscle incision was performed in female C57BL/6 mice treated daily with purified serum immunoglobulin G (IgG) from patients with longstanding CRPS or healthy volunteers followed by assessment of paw edema, hyperalgesia, inflammation, and central glial activation. CRPS IgG significantly increased and prolonged swelling and induced stable hyperalgesia of the incised paw compared with IgG from healthy controls. After a short-lasting paw inflammatory response in all groups, CRPS IgG-injected mice displayed sustained, profound microglia and astrocyte activation in the dorsal horn of the spinal cord and pain-related brain regions, indicating central sensitization. Genetic deletion of interleukin-1 (IL-1) using IL-1αβ knockout (KO) mice and perioperative IL-1 receptor type 1 (IL-1R1) blockade with the drug anakinra, but not treatment with the glucocorticoid prednisolone, prevented these changes. Anakinra treatment also reversed the established sensitization phenotype when initiated 8 days after incision. Furthermore, with the generation of an IL-1β floxed(fl/fl) mouse line, we demonstrated that CRPS IgG-induced changes are in part mediated by microglia-derived IL-1β, suggesting that both peripheral and central inflammatory mechanisms contribute to the transferred disease phenotype. These results indicate that persistent CRPS is often contributed to by autoantibodies and highlight a potential therapeutic use for clinically licensed antagonists, such as anakinra, to prevent or treat CRPS via blocking IL-1 actions.

Item Type: Article
Additional Information: Megosztott első és utolsó szerzőség Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, H-7624, Hungary János Szentágothai Research Centre, Centre for Neuroscience, University of Pécs, Pécs, H-7624, Hungary PharmInVivo Ltd., Pécs, H-7629, Hungary Faculty of Pharmacy, Department of Pharmacology, University of Pécs, Pécs, H-7624, Hungary Department of Biology and Electron Microscopy, Medical School, University of Pécs, Pécs, H-7624, Hungary Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, H-1083, Hungary Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, M13 9PT, United Kingdom Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, S10 2RX, United Kingdom Department of Translational Medicine, University of Liverpool, Liverpool, L9 7AL, United Kingdom Department of Pain Medicine, Walton Centre National Health Service Foundation Trust, Liverpool, L9 7LJ, United Kingdom Export Date: 22 July 2019 CODEN: PNASA Correspondence Address: Helyes, Z.; Department of Pharmacology and Pharmacotherapy, Medical School, University of PécsHungary; email: zsuzsanna.helyes@aok.pte.hu Funding details: 2017-2019, TAMOP Funding details: British Heart Foundation, BHF, PG/13/55/30365 Funding details: European Research Council, ERC, TÉT_16-1-2016-0104, CoG 724994 Funding details: KTIA_13_NAP-A-I/2 Funding details: Magyar Tudományos Akadémia, MTA Funding details: 2017-1.2.1-NKP-2017-00002 Funding text 1: ACKNOWLEDGMENTS. This research was supported by National Brain Research Program 2017-1.2.1-NKP-2017-00002 (NAP-2; Chronic Pain Research Group), the Pain Relief Foundation Liverpool, Gazdaságfejlesztési és Innovációs Operatív Program (Economy Development and Innovation Operative Programme) (GINOP)-2.3.2-15-2016-00050 (Peptidergic Signaling in Health and Disease; PEPSYS), Emberi Ero}forrás Operatív Program (Human Resource Operative Programme) (EFOP) 3.6.2-17-2017-00008 N (2017-2019), and Társadalmi Megújulás Operatív Program (Social Renewal Operative Programme) (TAMOP) 4.2.4. A/2-11-1-2012-0001 “National Excellence Program—Elaborating and operating an inland student and researcher personal support system convergence program.” Á.D. is supported by Hungarian Brain Research Program KTIA_13_NAP-A-I/2, the “Momentum” Program of the Hungarian Academy of Sciences, European Research Council (ERC)-CoG 724994, and TÉT_16-1-2016-0104. The generation of IL-1bfl/fl mouse line was funded by British Heart Foundation Grant PG/13/55/30365 (to E.P. and S.F.). We thank Dóra Ömböli and Lilla Draskóczi for their expert technical assistance in the animal experiments and tissue preparation; Jenny Hawkes for her expert technical assistance in the IgG preparation; and Deborah Bently for proofreading the manuscript. Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, H-7624, Hungary János Szentágothai Research Centre, Centre for Neuroscience, University of Pécs, Pécs, H-7624, Hungary PharmInVivo Ltd., Pécs, H-7629, Hungary Faculty of Pharmacy, Department of Pharmacology, University of Pécs, Pécs, H-7624, Hungary Department of Biology and Electron Microscopy, Medical School, University of Pécs, Pécs, H-7624, Hungary Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, H-1083, Hungary Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, M13 9PT, United Kingdom Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, S10 2RX, United Kingdom Department of Translational Medicine, University of Liverpool, Liverpool, L9 7AL, United Kingdom Department of Pain Medicine, Walton Centre National Health Service Foundation Trust, Liverpool, L9 7LJ, United Kingdom Export Date: 27 July 2019 CODEN: PNASA Correspondence Address: Helyes, Z.; Department of Pharmacology and Pharmacotherapy, Medical School, University of PécsHungary; email: zsuzsanna.helyes@aok.pte.hu Chemicals/CAS: immunoglobulin G, 97794-27-9; myeloperoxidase Funding details: 2017-2019, TAMOP Funding details: British Heart Foundation, BHF, PG/13/55/30365 Funding details: European Research Council, ERC, TÉT_16-1-2016-0104, CoG 724994 Funding details: KTIA_13_NAP-A-I/2 Funding details: Magyar Tudományos Akadémia, MTA Funding details: 2017-1.2.1-NKP-2017-00002 Funding text 1: ACKNOWLEDGMENTS. This research was supported by National Brain Research Program 2017-1.2.1-NKP-2017-00002 (NAP-2; Chronic Pain Research Group), the Pain Relief Foundation Liverpool, Gazdaságfejlesztési és Innovációs Operatív Program (Economy Development and Innovation Operative Programme) (GINOP)-2.3.2-15-2016-00050 (Peptidergic Signaling in Health and Disease; PEPSYS), Emberi Ero}forrás Operatív Program (Human Resource Operative Programme) (EFOP) 3.6.2-17-2017-00008 N (2017-2019), and Társadalmi Megújulás Operatív Program (Social Renewal Operative Programme) (TAMOP) 4.2.4. A/2-11-1-2012-0001 “National Excellence Program—Elaborating and operating an inland student and researcher personal support system convergence program.” Á.D. is supported by Hungarian Brain Research Program KTIA_13_NAP-A-I/2, the “Momentum” Program of the Hungarian Academy of Sciences, European Research Council (ERC)-CoG 724994, and TÉT_16-1-2016-0104. The generation of IL-1bfl/fl mouse line was funded by British Heart Foundation Grant PG/13/55/30365 (to E.P. and S.F.). We thank Dóra Ömböli and Lilla Draskóczi for their expert technical assistance in the animal experiments and tissue preparation; Jenny Hawkes for her expert technical assistance in the IgG preparation; and Deborah Bently for proofreading the manuscript. Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, H-7624, Hungary János Szentágothai Research Centre, Centre for Neuroscience, University of Pécs, Pécs, H-7624, Hungary PharmInVivo Ltd., Pécs, H-7629, Hungary Faculty of Pharmacy, Department of Pharmacology, University of Pécs, Pécs, H-7624, Hungary Department of Biology and Electron Microscopy, Medical School, University of Pécs, Pécs, H-7624, Hungary Momentum Laboratory of Neuroimmunology, Institute of Experimental Medicine, Budapest, H-1083, Hungary Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, M13 9PT, United Kingdom Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, S10 2RX, United Kingdom Department of Translational Medicine, University of Liverpool, Liverpool, L9 7AL, United Kingdom Department of Pain Medicine, Walton Centre National Health Service Foundation Trust, Liverpool, L9 7LJ, United Kingdom Export Date: 27 August 2019 CODEN: PNASA Correspondence Address: Helyes, Z.; Department of Pharmacology and Pharmacotherapy, Medical School, University of PécsHungary; email: zsuzsanna.helyes@aok.pte.hu Chemicals/CAS: immunoglobulin G, 97794-27-9; myeloperoxidase Funding details: 2017-2019, TAMOP Funding details: British Heart Foundation, BHF, PG/13/55/30365 Funding details: European Research Council, ERC, TÉT_16-1-2016-0104, CoG 724994 Funding details: KTIA_13_NAP-A-I/2 Funding details: Magyar Tudományos Akadémia, MTA Funding details: 2017-1.2.1-NKP-2017-00002 Funding text 1: ACKNOWLEDGMENTS. This research was supported by National Brain Research Program 2017-1.2.1-NKP-2017-00002 (NAP-2; Chronic Pain Research Group), the Pain Relief Foundation Liverpool, Gazdaságfejlesztési és Innovációs Operatív Program (Economy Development and Innovation Operative Programme) (GINOP)-2.3.2-15-2016-00050 (Peptidergic Signaling in Health and Disease; PEPSYS), Emberi Ero}forrás Operatív Program (Human Resource Operative Programme) (EFOP) 3.6.2-17-2017-00008 N (2017-2019), and Társadalmi Megújulás Operatív Program (Social Renewal Operative Programme) (TAMOP) 4.2.4. A/2-11-1-2012-0001 “National Excellence Program—Elaborating and operating an inland student and researcher personal support system convergence program.” Á.D. is supported by Hungarian Brain Research Program KTIA_13_NAP-A-I/2, the “Momentum” Program of the Hungarian Academy of Sciences, European Research Council (ERC)-CoG 724994, and TÉT_16-1-2016-0104. The generation of IL-1bfl/fl mouse line was funded by British Heart Foundation Grant PG/13/55/30365 (to E.P. and S.F.). We thank Dóra Ömböli and Lilla Draskóczi for their expert technical assistance in the animal experiments and tissue preparation; Jenny Hawkes for her expert technical assistance in the IgG preparation; and Deborah Bently for proofreading the manuscript.
Uncontrolled Keywords: Interleukin-1; autoantibody; Anakinra; complex regional pain syndrome; CRPS;
Subjects: R Medicine / orvostudomány > R1 Medicine (General) / orvostudomány általában
SWORD Depositor: MTMT SWORD
Depositing User: MTMT SWORD
Date Deposited: 25 Sep 2019 13:00
Last Modified: 25 Sep 2019 13:00
URI: http://real.mtak.hu/id/eprint/101199

Actions (login required)

Edit Item Edit Item